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Abstract
Background: Despite medical advances, major surgery remains high risk with up to 44% of patients experiencing
postoperative complications. Early recognition of postoperative complications is crucial in reducing morbidity and
preventing long-term disability. The current standard of care is intermittent manual vital signs monitoring, but new
wearable remote monitors offer the benefits of continuous vital signs monitoring without limiting the patient’s
mobility. The aim of this study was to evaluate the feasibility, acceptability and clinical outcomes of continuous
remote monitoring after major surgery.
Methods: The study was a randomised, controlled, unblinded, parallel group, feasibility trial. Adult patients
undergoing elective major surgery were randomly assigned to receive continuous remote monitoring and normal
National Early Warning Score (NEWS) monitoring (intervention group) or normal NEWS monitoring alone (control
group). Continuous remote monitoring was achieved using the SensiumVitals® wireless patch which is worn on the
patient’s chest and monitors heart rate, respiratory rate and temperature continuously, and alerts the nurse when
there is deviation from pre-set physiological norms. Feasibility was assessed by evaluating recruitment rate,
adherence to protocol and randomisation and the amount of missing data. Clinical outcomes included time to
antibiotics in cases of sepsis, length of hospital stay, number of critical care admissions and rate of hospital
readmission within 30 days of discharge.
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Results: One hundred and thirty-six patients were randomised between October 2018 and April 2019: 67 to the
control group and 69 to the intervention group. Recruitment was completed prior to the 12 month target with a
high rate of eligibility and consent. Missing data was limited only to questionnaire responses; no participants were
lost to follow-up and only one participant was withdrawn due to loss of capacity. The number of patients classed
as ‘drop-out’ due to design (8.1%) were less than anticipated, and there were no participants who crossed over into
the alternative trial allocation group. Seventeen participants in the intervention group (28%) did not adhere to the
monitoring protocol. No formal comparisons between arms was undertaken; however, participants had fewer
unplanned critical care admissions (1 versus 5) and had a shorter average length of hospital stay (11.6 days (95%
confidence interval 9.5–13.7 days) versus 16.2 days (95% confidence interval 11.3–21.2 days)) in the continuous vital
signs monitoring group. The time taken to receive antibiotics in cases of sepsis was similar in both arms. A cost-
utility analysis indicated that the remote monitoring system was cost-saving when compared to standard NEWS
monitoring alone.
Conclusions: It is feasible to perform a large-scale randomised controlled trial of continuous remote monitoring
after major surgery. Progression to a definitive multicentre randomised controlled trial would be appropriate, taking
consideration of factors, such as patient adherence, that might mask the potential benefit of additional monitoring.
Trial registration: ISRCTN registry with study ID ISRCTN16601772. Registered 30 August 2017.
Keywords: Continuous, Early warning score, Feasibility, Vital signs, Monitoring, Surgery, Complications
Key messages regarding feasibility
 What uncertainties existed regarding the feasibility?
A wearable wireless continuous monitoring system
was implemented on an elective general surgical
ward, and compared to traditional intermittent vital
signs monitoring. Prior to the design of a
multicentre randomised controlled trial to assess the
effectiveness of continuous monitoring on patient
outcomes, we aimed to assess the feasibility of the
study protocol on recruitment, estimated
recruitment rate, levels of adherence to protocol,
estimated amount of missing data and potential
optimal outcome measures.
 What are the key feasibility findings?
The findings of this feasibility study suggest that
progression to a definitive multicentre randomised
controlled trial would be appropriate. There were
high rates of patient recruitment. There were fewer
than anticipated ‘drop-outs’ and no participants
crossed over into the alternative trial allocation
group. Missing data was also limited; no participants
were lost to follow-up and only one participant was
withdrawn. Patient acceptability was excellent, al-
though patient adherence to protocol could be
improved.
 What are the implications of the feasibility findings
for the design of the main study?
Participants should be individually randomised and
stratified to minimise the baseline differences
between the two treatment arms; ASA might be
replaced by more specific risk stratification tools.
The intra-cluster correlation co-efficient should be
taken into account in the sample size calculation to
account for potential clustering of outcomes at bay
or ward level. Care should also be taken to monitor
and address inadequacies in other areas that might
mask the potential benefit of additional monitoring,
such as patient adherence.
Background
Patients having major surgery are at high risk of compli-
cations, some of which can be life-threatening. Rates of
complications can be as high as 33–44% in patients
undergoing surgery for gastro-intestinal cancers [1]. Pa-
tients who develop postoperative complications become
progressively unwell, often over a short period of time.
Early recognition of postoperative complications is cru-
cial in reducing morbidity and preventing long-term dis-
ability; for patients with septic shock, there is an 8%
increase in mortality for every hour of delay in antibiotic
administration [2]. Early detection and treatment of
complications minimises the need for Level II/III care
and produces significant cost savings [3].
The recording of patients’ vital signs is a key aspect of
monitoring for complications. In England, the National
Early Warning Score (NEWS) is the standard of care
recommended by the Royal College of Physicians [4].
Vital sign scores are summated to provide a numerical
score that gives an indication of the patient’s physio-
logical status. Typically, in the postoperative period,
NEWS will be calculated half hourly for the first few
hours; if the patient remains stable, the frequency will
decrease to 2-hourly and then 4-hourly, until the patient
is ready for discharge when the NEWS may be recorded
only twice a day.
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Although NEWS has proven benefit, it suffers from
several drawbacks [5]. NEWS relies on manual observa-
tions, is time-consuming and open to user interpret-
ation. Vital signs are taken at predetermined intervals
with patient deterioration possible between recordings.
It has been suggested that the gap between observations
is one of the primary failings of the NEWS system [6].
A solution to the problem of inadequate monitoring
frequency is continuous monitoring at the bedside. Until
recently, continuous monitoring has been limited to
Level II/III care due to its cost and limitations to patient
mobilisation [7]. Recent advances in wearable technology
have heralded the advent of remote wireless monitors. It
is hypothesised that the remote continuous monitoring
system, as an adjunct to standard vital signs monitoring,
will allow earlier detection of patient deterioration. This
should reduce morbidity, which in turn should result in
a decreased need for Level II/III care.
Demonstrating significant benefit over intermittent
monitoring to offset the practical and economic
implications of continuous monitoring requires large,
well-controlled studies in high-risk populations to
demonstrate significant differences in clinical out-
comes, such as critical care admissions. Given the
complexity of the intervention, before a definitive trial
is designed, there is the need for a feasibility study fo-
cussed on not only clinical outcome measures but also
patient acceptability and adherence. In addition, a
feasibility study will allow the identification of barriers
to recruitment, estimate protocol adherence and allow
optimisation of the technology and trial design.
The main aim of the study was to determine the feasi-
bility of performing a large-scale individually randomised
controlled trial of continuous remote monitoring after
major surgery. Secondary aims were to informally assess
the potential safety, potential efficacy, acceptability and
potential cost utility of a wearable, remote monitoring
system for patients after major surgery, as compared to
standard monitoring with the NEWS system alone.
Methods
Ethical approval and consent to participate
Ethical approval was granted on 10th October 2017 by
the Yorkshire & The Humber–Leeds West Research
Ethics Committee, ref: 17/YH/0180. Informed written
consent to participate was obtained from all participants
in the study.
Trial design
This was a single-centre, feasibility, randomised, con-
trolled, parallel group trial of continuous remote vital
signs monitoring for patients undergoing major elective
general surgery. Participants were individually rando-
mised on a 1:1 basis to receive either remote monitoring
plus NEWS or monitoring by NEWS alone. The planned
recruitment period was 12 months. Participant follow-up
extended to 30 days after hospital discharge.
The study was registered on the ISRCTN registry
(ISRCTN 16601772). The study protocol has been
published separately [8]. No changes were made to the
registered protocol. The trial was performed in accord-
ance with Good Clinical Practice guidelines and the
Declaration of Helsinki, and is presented according to
the CONSORT statement principles [9] and the
CONSORT 2010 extension to randomised pilot and
feasibility trials [10].
Study setting
All participants were recruited on the admissions ward
at St James’s University Hospital, Leeds, United
Kingdom.
Eligibility criteria
Patients were selected on the basis that they were under-
going elective major abdominal surgery. Patients were
identified, recruited and consented for inclusion in the
trial on the day of their surgery by a research nurse or a
clinical fellow.
Inclusion criteria
 Patients undergoing elective abdominal surgery
 Patients with the capacity to provide informed,
written consent on admission
 All ages ≥ 18 years
Exclusion criteria
 Patients undergoing emergency surgery
 Allergy to adhesives on electrodes
 Cardiac pacemaker in situ
Randomisation
Following confirmation of eligibility and written in-
formed consent, participants were randomised into the
trial by a research nurse or clinical fellow. Randomisa-
tion was performed centrally using the University of
Leeds Clinical Trials Research Unit (CTRU) 24-h
randomisation service, either via the telephone or the
CTRU website.
Participants were randomised on a 1:1 basis and
allocated a unique trial number. Randomisation was
conducted using permuted stratified block randomisa-
tion with variable block size with gender (male/female)
and ASA grade (grades 1–4) as stratification factors.
The randomisation sequence was generated by a statis-
tician in the Leeds Clinical Trials Research Unit and
computer-generated using SAS 9.4 (SAS Institute Inc.,
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United States of America, 2013). This sequence was im-
plemented and delivered by programmers through the
Leeds CTRU Gen24 system, a dedicated telephone and
web-based randomisation service.
Interventions
Patients randomised to the intervention arm received a
SensiumVitals® remote monitoring patch and standard
NEWS monitoring. The SensiumVitals® patch monitors
heart rate, respiratory rate and temperature continu-
ously. The data are transmitted wirelessly every 2 min to
a mobile device carried by the nurse that alerts when
there is deviation from pre-set physiological norms. Al-
though there are a number of similar devices on the
market, the SensiumVitals® system was chosen for evalu-
ation in this work as it is CE-marked and the company
was in a position to support a timely evaluation before
aiming for widespread adoption.
The patch was applied as soon as possible after the pa-
tient came out of theatre. Participants admitted to Level
II/III care after surgery had the patch activated once
they returned to a participating Level I ward.
Two surgical wards participated in the study: male and
female. The male ward housed 25 beds, whilst the fe-
male ward housed 28 beds. The patch was activated on
arrival to the ward and the patient’s nurse carried a mo-
bile device to alert them if the vital signs strayed outside
of normal parameters. Remote monitoring data were
also accessible on the ward computer screens for wider
access. There was no dedicated telemetry screen for the
patch data. Nursing staff were provided with thorough
training before the commencement of the study. If the
mobile devices alerted the nursing staff to abnormal vital
signs, the ensuing clinical response was not mandated,
but left to the nurse’s discretion within the boundaries
of hospital protocols.
Patients in the control arm received standard NEWS
monitoring alone. All usual nursing and medical care
were permitted within both arms of the trial.
The patients were to remain in their allocated study
arm for the duration of their hospital stay. If a remotely
monitored patient was moved to a critical care bed dur-
ing their admission, the remote monitoring was tempor-
arily suspended pending reinstatement if they returned
to a participating ward. Every effort was made to ensure
that participants remained in the study arm to which
they were originally allocated, and any non-adherence
was recorded.
Blinding
Blinding was not applicable for this study. Neither the
patients nor the nursing staff could be blinded to the
intervention received. The data collection was performed
by a research nurse and clinical fellow, who were both
administering the monitoring device, and so were neces-
sarily unblinded. However, the objective methods of col-
lecting the outcome data minimised the risk of bias.
These data were taken from the clinical records made by
the patients’ usual care teams, including a succession of
junior medical staff on rotation, who were unaware of
the study. In addition, the predefined criteria for the out-
come measures provided minimal scope for interpret-
ation of their presence or absence by the data collection
team. The clinical fellow performed the analysis along-
side an unblinded statistician.
Primary outcome measures
There were no changes to the outcome measures pre-
specified in the published protocol [8]. Outcome mea-
sures were assessed after the trial had closed. No interim
analyses were performed. The primary outcome mea-
sures were:
 Recruitment rate
 Information on the ideal method of randomisation,
which will include calculation of intra-cluster correl-
ation co-efficient to investigate whether there is any
inherent clustering in outcomes based on which
ward bay a participant is admitted to.
 Adherence to protocol, and reasons for non-
adherence, as defined by the number of patients
who do not receive the correct type of monitoring
as per randomisation (and reasons for this) and the
number of patients who do not wear the patch for
their entire hospital stay or at least 5 days during
their admission.
 Amount of missing clinical data and loss-to-follow-
up.
 Optimal outcome measures to test efficacy as
assessed by the amount of missing data and the
summary statistics for each potential outcome.
 Estimation of parameters to input into the sample
size calculation for a definitive trial.
Secondary outcome measures
The secondary outcome measures were:
 Number of postoperative complications, defined and
scored according to the Clavien-Dindo classification
of surgical complications [11].
 Number of reinterventions, defined and scored
according to the Clavien-Dindo classification of
surgical complications.
 Time to antibiotics in cases of sepsis, as defined by
the presence of a likely source of infection and 2 or
more of the following criteria: temperature > 38.3 °C
or < 36.0 °C, tachycardia > 90 beats per minute,
tachypnoea > 20 breaths per minute, pCO2 < 4.3
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kPa, hyperglycaemia (blood glucose > 6.6 mmol/L)
in the absence of diabetes mellitus, acutely altered
mental status, white blood cell count > 12 × 109/L
or < 4 × 109/L [12].
 Number of HDU/ICU admissions.
 Length of stay in HDU/ICU.
 Total length of stay in hospital.
 30-day hospital readmission rate.
 Patient acceptability assessed using a questionnaire
and by calculating the number of patients not
wearing a patch for at least 5 days.
 The comparative cost-effectiveness of the Sensium-
Vitals® remote monitoring system versus standard
NEWS monitoring from an NHS payer perspective.
Sample size
As the trial was designed to assess the feasibility of con-
ducting a future definitive large-scale trial, a formal
power calculation was not considered appropriate as effi-
cacy was not being formally evaluated.
The simulation work of Teare et al. [13] recommends
that 60 participants per group is sufficient to estimate
event rates in feasibility trials with binary endpoints.
This work provides the justification of the sample size of
at least 120 subjects in a two-armed study. It was antici-
pated that a binary endpoint would be the outcome
measure of interest; for continuous endpoints, however,
a smaller sample of 70 participants (35 per group) would
have been sufficient.
It was anticipated that 20% of participants would not
be admitted to a participating ward; these participants
were classed as ‘drop-out’ due to design, and were not
included in the modified intention-to-treat analysis.
Planned analyses
Analysis was carried out following the principles of
modified intention-to-treat (ITT). The modified ITT
(mITT) population included all participants randomised
to the trial, analysed according to the treatment group
to which they were randomised, regardless of adherence
to the protocol. The modified ITT (mITT) population
excluded any participants who were classed as ‘drop-out’
due to design (i.e. those who were never admitted to a
participating ward).
Baseline characteristics were summarised descriptively
overall and by trial arm. Quantitative secondary outcome
measures were summarised descriptively using appropri-
ate summary statistics both overall and by trial arm
(mean, standard deviation, range and median for con-
tinuous outcomes and frequency and percentages for
categorical measures). Proportions of missing data are
also presented. Missing data does not refer to missing
sensor data, only to missing clinical data as collected on
the Case Report Forms.
As this is a feasibility study, no formal comparison be-
tween the study arms was undertaken. Summaries were
produced by subgroup to determine any differences be-
tween low- and high-risk patients. High-risk patients
were defined as ASA > 2 undergoing Major+ surgery, or
ASA ≥ 2 with a perioperative critical care admission.
Analysis was carried out in SPSS (Version 23.0 or later,
IBM Corp., New York, USA), apart from the ICC calcula-
tions and the sample size calculations. The ICC was esti-
mated from a one-way analysis of variance (ANOVA) in
Stata (Release 17, StataCorp, Texas, USA) using a cluster
size of 7. This cluster size was chosen as it represents the
mean number of patients in each bay (range 4–8).
An estimation of the sample size for a definitive trial
was calculated using a two-group Satterthwaite t test of
equal means and unequal variances using NQuery (Ver-
sion 3.0, Statistical Solutions Ltd., Massachusetts, USA).
A cost-utility analysis was conducted using decision-
analytic modelling. The base-case analysis took an NHS
perspective and the time horizon for the model was 6
weeks post-surgery. The model is provided in Additional
file 1. Transition probabilities for the model were taken
exclusively from the study data. A targeted literature
search was conducted to identify relevant studies that re-
ported data for the model parameters for costs and util-
ity values (details available on request from the
corresponding author). Outcomes comparing the Sen-
siumVitals® remote monitoring system with standard
NEWS monitoring were presented as incremental cost-
effectiveness ratios (ICERs). To characterise uncertainty
in the model parameters, a probabilistic sensitivity ana-
lysis was carried out, based on ten thousand simulations
parameterizing the model from the pre-specified param-
eter distributions. The simulated ICERs were presented
in a cost-effectiveness plane. All analyses were con-
ducted in Microsoft Excel (Microsoft Corporation, Red-
mond, WA, USA). The cost-effectiveness plane was
produced in R (Version 3.4.1, R Foundation for Statis-
tical Computing, Massachusetts, USA).
Progression criteria
The pre-specified criteria to indicate that progression to
a definitive randomised controlled trial would be feasible
were:
 The recruitment of 120 patients within 12 months
who received monitoring on the trial
 Missing data limited to no more than 20% attrition
(drop-out by design, loss to follow-up or withdrawal
from monitoring)
Results
One hundred and thirty-six patients were included in the
study between October 2017 and April 2018. Follow-up
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ended in May 2018. A patient flow chart is presented in
Fig. 1, and patient characteristics in Table 1.
Of the 173 patients assessed for eligibility, 24 were ex-
cluded prior to approach because they did not meet the
inclusion criteria: ten patients went to theatre before ap-
proach; seven patients had a pacemaker; four patients
were in source isolation; two patients lacked capacity;
one patient was in a conflicting research trial. Of the
149 patients approached, 13 declined to participate be-
cause they did not want to be involved in research in
general or because they felt too anxious about their
impending surgeries.
Consent was obtained from 136 patients, all of whom
were subsequently randomised. Sixty-seven patients
were allocated to receive continuous monitoring along-
side standard care. Sixty-nine patients were allocated to
the control group.
Eleven patients were excluded from the modified
intention-to-treat population. These were patients who
had their surgery cancelled on the day (n = 2: one
participant per arm) or who did not return to a partici-
pating ward (n = 9: six in the intervention arm, three in
the control arm). The modified intention-to-treat popu-
lation consisted of 60 participants in the intervention
arm, and 65 participants in the control arm. One partici-
pant was withdrawn from the study when they lost cap-
acity to consent in the post-operative period and did not
regain capacity; this participant was in the intervention
arm.
The participant characteristics at baseline were well
balanced across both arms of the study (Table 1). Both
arms were similar in terms of the types of surgery the
participants underwent. Further details on the type of




The eligibility rate of all considered patients was 86.1%
(13.9% of patients were ineligible). The recruitment rate
was 91.3% out of those eligible. The proportion of pa-
tients who were classed as ‘drop-out’ by design was
8.1%. The trial recruited to target and ahead of time.
Fig. 1 CONSORT flow diagram for the trial (*Early discontinuation of the intervention was defined as not wearing a patch for at least 5 days or
until discharge from hospital)
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Assessment of randomisation
The intra-cluster correlation co-efficient was calculated
based on 121 observations; participants who were trans-
ferred between different bays during their admission (n
= 3) were excluded from this analysis, as was the partici-
pant who was withdrawn from the study (n = 1). Length
of hospital stay was chosen as the outcome measure of
interest for this analysis for three reasons:
1) It is an outcome likely to be of relevance in a
definitive study
2) There were likely to be data for every participant in
the trial
3) Other potential candidates for the primary outcome
in a definitive study were likely to exhibit too few
events in the feasibility trial to calculate a
meaningful ICC. This includes outcome measures
such as readmission rates, time to antibiotics in
sepsis and critical care admissions
The ICC was found to be moderate (ICC = 0.06150,
95% CI = 0, 0.18839), indicating that the bay into which
a participant was admitted had some effect on their
length of hospital stay.
Adherence to protocol
Participants in the control arm were 100% adherent to
protocol. From the intervention arm, 17 participants
(28.3%) did not adhere to protocol. Eight participants
(13.3%) did not receive the intervention at any point
during their admission as they declined the patch after
their return to the ward. Of note, 7 of the 8 participants
who did not have the patch applied were categorised as
high-risk. Nine participants discontinued the interven-
tion before discharge and within 5 days of application.
Reasons for this included patient discomfort or skin re-
action (n = 5), too many false alerts (n = 2), transfer to
non-participating ward (n = 1) and incorrect assumption
of imminent discharge (n = 1).
Amount of missing clinical data and loss-to-follow-up
No participants were lost to follow-up. One participant
was withdrawn from the study after they lost capacity to
consent during their hospital admission; no further study
data was collected after the participant lost capacity.
Data up to the point of lost capacity has been included
in the analysis. Missing data was limited to questionnaire
responses; 14 patients did not fill in the questionnaire as
they left hospital before it could be administered.
Optimal outcome measures to test efficacy
Assessment of the optimal outcome measures took into
consideration the amount of missing data and summary
statistics for each potential outcome. Two potential out-
come measures displayed compelling differences be-
tween the two trial arms: rate of critical care admission
and length of hospital stay. There was no missing data
Table 1 Baseline patient characteristics and intraoperative demographics
NEWS alone n = 65 SensiumVitals® + NEWS n = 60 Total n = 125
Males n (%) 35 (28.0%) 31 (24.8%) 66 (52.5%)
Females n (%) 30 (24.0%) 29 (23.2%) 59 (47.2%)
Age (mean, range) 62 (22 – 87) 65 (36–85) 63 (22–87)
ASA n (%)
1 6 (4.8%) 4 (3.2%) 10 (8.0%)
2 40 (32.0%) 39 (31.2%) 79 (63.2%)
3 19 (15.2%) 17 (13.6%) 36 (28.8%)
4 0 0 0
Not documented 0 0 0
Type of surgery
Colonic resection 55 (44.0%) 53 (42.4%) 108 (86.4%)
Small bowel resection 1 (0.8%) 3 (2.4%) 4 (3.2%)
Other* 9 (7.2%) 4 (3.2%) 13 (10.4%)
Mode of surgery for colonic resections
Laparoscopic 32 (25.6%) 32 (25.6%) 64 (51.2%)
Open 18 (14.4%) 17 (13.6%) 35 (28.0%)
Converted 3 (2.4%) 2 (1.6%) 5 (4.0%)
Assisted 2 (1.6%) 2 (1.6%) 4 (3.2%)
*Further details on the type of surgery undergone by the participants is presented in Additional file 2
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for any of these outcome measures; however, data from
the one withdrawn participant was censored at the time
of withdrawal, forfeiting data regarding their length of
hospital stay and any subsequent complications.
Estimation of parameters to input into the sample size
calculation for a definitive RCT
Estimation of the sample size range for a definitive trial
was calculated using the observed effect sizes for length
of hospital stay.
Based on the mean length of hospital stay from the
feasibility study data and using the point estimate for the
ICC, the target sample size for a definitive trial was cal-
culated as 602 participants (301 per arm), which pro-
vides 80% power at the 5% significance level to detect a
2-day difference in length of hospital stay, allowing for
15% attrition. To provide 90% power, 808 participants
would be required (404 per arm). Further sample size
calculations using the limits of the confidence intervals
for the ICC and the chosen endpoint are provided as
Additional file 3.
Secondary outcome measures
Postoperative complications and reinterventions
There were more complications in the control arm than
the intervention arm in every Clavien-Dindo classifica-
tion grou p[11], as summarised in Table 2. This was es-
pecially evident in the number of participants
experiencing major complications (Clavien-Dindo III or
IV): 10 in the control arm (15.5%) versus 3 in the inter-
vention arm (5.0%).
The proportion of participants receiving at least one
re-intervention, as defined by the Clavien-Dindo
complications classification, was 76.9% in the control
arm and 80.0% in the intervention group.
Time to antibiotics in cases of sepsis
From the modified intention-to-treat population, 35 par-
ticipants were suspected of having sepsis at least once
during their hospital admission: 16 from the control arm
(24.6%) and 19 from the intervention arm (31.7%). Of
these, sepsis was confirmed in 22 cases. Twenty-one pa-
tients received antibiotics: 9 from the control arm (75%)
and 12 from the intervention arm (52.5%). The sources
of sepsis are provided as Additional file 4.
The mean time to antibiotics was 527 min in the con-
trol arm (range 56–1474 min, 95% CI 199 min, 856 min)
and 551 min in the intervention arm (range 14–1165
min, 95% CI 296 min, 805 min).
In the intervention arm, 5 out of 19 events were first
identified by the SensiumVitals® remote monitoring sys-
tem (26.3%). The remaining events were first identified
by the NEWS system.
HDU/ICU admissions
Six participants were admitted to HDU or ICU from a
participating ward following surgery. Five participants
were from the control arm with an average critical care
stay of 3 days. One participant was from the intervention
arm; their length of stay in critical care is unknown as
they were withdrawn from the study due to lack of
capacity (see Table 3).
Total length of stay in hospital
As shown in Table 3, participants in the control arm
had a longer average length of hospital stay (16.2 days,
Table 2 Summary of postoperative complications and reinterventions
NEWS alone n =
65




Number of complications (all) 180 124 304
I 85 59 144
II 82 62 144
IIIa 3 1 4
IIIb 5 1 6
IVa 3 0 3
IVb 2 1 3
Number of participants experiencing major complications (Clavien-Dindo >
II)
13 (10.4%) 4 (3.2%) 17 (13.6%)
Number of reinterventions
Medical 170 121 291
Radiological 3 1 4
Surgical 7 2 9
Total 180 124 304
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95% CI 11.3 days, 21.2 days) compared to those in the
intervention arm (11.6 days. 95% CI 9.5 days, 13.7 days).
Thirty-day readmission rate
Eleven participants (8.9%) were readmitted to hospital
within 30 days of discharge from their index admission.
Five were from the control arm (7.7%, 95% CI 2.5%,
17.0%) and six from the intervention arm (10.2%, 95%
CI 3.8%, 20.8%). All readmissions were emergency
admissions.
Subgroup analysis of secondary outcome measures
In the pre-specified subgroup analysis, the intervention
arm had a slightly higher proportion of high-risk partici-
pants (48.3%) than the control arm (41.5%) (Table 4).
Table 3 Summary of critical care admissions, length of hospital stay, readmission rates and deaths
NEWS alone n = 65 SensiumVitals® + NEWS n = 60
Level II/III admissions
n 5 1
Length of stay in Level II/III (days)
Mean (s.d.) 3 (2.0) (.)a
Length of stay in hospital (days)
Mean (s.d.) 16.2 (20.3) 11.6 (8.2)
95% confidence interval 11.3–21.2 9.5–13.7
Readmissionsb
n (%) 5 (7.7%) 6 (10.2%)
95% confidence interval 2.5– 17.0% 3.8– 12.8%
Inpatient deaths 0 1
aThe length of stay in Level II/III is unknown for this participant as they were withdrawn due to loss of capacity
bThe denominator for readmissions was the total number of participants in each respective arm of the study; however, readmission data was not collected for the
participant who was withdrawn from the study









n (%) 27 (41.5%) 29 (48.3%) 38 (58.5%) 31 (51.7%)
Number of complications (all) 91 70 89 54
Number of major complications
(Clavien-Dindo > 2)
8 3 5 0
Sepsis events n (%) 8 (29.6%) 12 (41.4%) 8 (21.1%) 7 (22.6%)
Time to antibiotics in cases of sepsis (minutes)
n 6 5 6 4
Mean 588 433 466 697
95% confidence interval 0–1247 54– 813 281– 651 381– 1013
HDU/ICU admissions
n 4 1 1 0
Length of stay in HDU/ICU (days)
Mean 3.5 (.)a 1 N/A
Length of stay in hospital (days)
n 27 28 38 31
Mean 23.3 15.7 11.2 7.9
95% confidence interval 12.4–34.2 11.9–19.5 8.8–13.7 7.1–8.6
Readmissions
n (%) 4 (14.8%) 4 (14.3%) 1 (2.6%) 2 (6.5%)
95% confidence interval 4.2–33.7% 4.0–32.7% 0.1–13.8% 0.8–21.4%
aThe length of stay in Level II/III is unknown for this participant as they were withdrawn due to loss of capacity
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Of the high-risk participants, those in the control arm
experienced more unplanned critical care admissions,
but fewer sepsis events than those in the intervention
arm. High-risk participants in the control arm had a lon-
ger average length of hospital stay (23.3 days, 95% CI
12.4, 34.2 days) compared to those in the intervention
group (15.7 days, 95% CI 11.9, 19.5 days), but were no
more likely to be readmitted back to hospital within 30
days of discharge.
Subgroup analysis of low-risk participants revealed
similar trends across all secondary outcome measures:
lower rates of major complications, sepsis events and
critical care admissions in the intervention group.
Low-risk participants in the control arm had a longer
average length of hospital stay (11.2 days, 95% CI 8.8,
13.7 days) compared to those in the intervention
group (7.9 days, 95% CI 7.1, 8.6 days), but were less
likely to be readmitted back to hospital within 30
days of discharge. These findings are summarised in
Table 4.
Patient acceptability
Of the 52 participants who wore the patch, 7 discontin-
ued wear due to discomfort (n = 5) or inconvenience
from false alerts (n = 2). The patient acceptability ques-
tionnaire was completed by 46 participants (88.5%).
Fourteen participants did not complete the question-
naire as they were discharged from hospital before the
questionnaire was administered. Most participants found
the patch comfortable and felt safer wearing it, as shown
in Figs. 2 and 3.
Cost-effectiveness
At the 6-week time horizon, the SensiumVitals® remote
monitoring system was cost-saving when compared to
standard NEWS monitoring from an NHS payer
perspective. The ICER was £1,460 (95% CI − £6,780, £9,
701) per every one-point increase in overall quality of
life on the abbreviated World Health Organization Qual-
ity of Life (WHOQOL-BREF) score. For the probabilistic
sensitivity analysis, the results of the Monte-Carlo simu-
lations are shown in the reference. This analysis indi-
cates that the probability of cost-saving is 69.9% and the
probability of benefit to quality of life is 58% (Fig. 4).
Progression criteria
The criteria for progression to a definitive randomised
controlled trial were met.
 The recruitment of over 120 patients was achieved
well within 12 months. The study opened to
recruitment on 20th October 2017 and closed on
10th April 2018 with 125 participants receiving
monitoring on the trial.
 Missing data was limited only to questionnaire
responses; no participants were lost to follow-up.
One participant was withdrawn due to loss of
capacity.
Discussion
In this single-centre randomised controlled feasibility
trial, the feasibility of performing a large-scale rando-
mised controlled trial of continuous remote monitoring
after major surgery has been confirmed.
A number of uncertainties on feasibility existed prior
to this study: feasibility of recruitment, estimated re-
cruitment rate, levels of adherence to protocol, estimated
amount of missing data and potential optimal outcome
measures. These uncertainties have been addressed by
the study’s key findings.
The recruitment target was met within 6 months with
a high rate of eligibility and consent; the recruitment
Fig. 2 Responses to the statement, ‘The patch is comfortable to wear’
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rate was higher than expected. The number of patients
classed as ‘drop-out’ due to design were less than antici-
pated and no participants crossed over into the alterna-
tive trial allocation group. Missing data was limited only
to questionnaire responses; no participants were lost to
follow-up and one participant was withdrawn due to loss
of capacity.
The rate of critical care admissions and length of hos-
pital stay are potential primary outcome measures for a
definitive trial. Length of hospital stay data are applicable
to every participant and, using the summary statistics
from this feasibility study, shows a high likelihood of
demonstrating efficacy over intermittent monitoring
alone. It is an outcome measure that is relevant for the
individual patient, society and the healthcare system.
However, the effect on length of hospital stay may not
be directly attributable to the intervention.
In contrast, the rate of critical care admissions is an
outcome measure that can more easily be attributed to
the intervention. By alerting the healthcare provider at
the earliest sign of deterioration, continuous monitoring
may detect complications earlier than intermittent vital
signs monitoring, allowing for prompt treatment and po-
tentially reducing the need for Level II/III care. How-
ever, the event rate, even in a high-risk population, is
likely to be low, necessitating an inflated sample size
Fig. 4 Cost-effectiveness plane
Fig. 3 Responses to the statement, ‘I felt safer wearing the patch’
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with its associated costs; however, recruitment to a
higher target is likely to be successful given the high
consent rates in the feasibility study. Practically, it may
be difficult to implement given that different hospitals
have different admission and discharge criteria to critical
car e[14], which may produce a further clustering effect.
In this study, the intra-cluster correlation co-efficient
and the balanced preoperative demographics between
arms suggest that the randomisation method employed
in the trial was appropriate. Of interest is the fact that,
despite using ASA grade as a stratification factor, there
were more postoperative complications in the control
arm than the intervention arm in every Clavien-Dindo
classification group. Whilst the difference in the number
of participants experiencing major complications
(Clavien-Dindo III or IV) could be explained by the
intervention preventing escalation of care in the event of
complications, the difference in the minor complications
(Clavien-Dindo I and II) is less predictable. Possible
causes of these differences include the intervention pre-
venting escalation of complications; a failure of random-
isation, which may indicate that the ASA score is not
sufficiently specific to stratify participants in terms of
their risk; or that the complications occurred by chance,
in which case larger numbers of participants would be
required to avoid this risk in a definitive trial.
The moderate ICC estimate indicates that there is
some effect of clustering on the endpoint selected
(length of hospital stay) based on which bay a participant
was admitted to. The ICC and the confidence interval
limits were used to calculate a sample size range for a
potential definitive trial. Using mean length of hospital
stay as the primary endpoint would require a sample size
of 602 participants (301 per arm), which provides 80%
power at the 5% level of significance to detect a 2-day
difference in length of hospital stay, allowing for 15%
attrition to account for participants who drop out by de-
sign and those who withdraw from monitoring during
the study (12.8% of the study sample in the feasibility
trial). The sample size calculation uses the ICC esti-
mated from the feasibility study, and refers to bays as
the clusters in question. In a definitive trial, clusters may
be larger; for instance, randomisation may be clustered
by wards rather than bays. In this case, larger clusters
may require higher numbers of participants to maintain
80% power.
A secondary objective was to evaluate the safety,
potential efficacy and acceptability of a wearable, remote
monitoring system for patients after major surgery, as
compared to standard monitoring with the NEWS
system alone. Previous studies evaluating continuous
monitoring of multiple vital signs parameters have
shown mixed results. An industry-funded controlled
before-and-after study of 7643 patients [15] found that
continuous monitoring on a medical-surgical unit was
associated with a decrease in total ICU days, but the rate
of ICU admission was unchanged. A randomised
controlled trial of 402 high-risk medical and surgical pa-
tients found that continuous multi-parameter
monitoring showed no effect on adverse events or mor-
tality [3].
In this study, participants who had undergone major
abdominal surgery were less likely to have an unplanned
critical care admission and had a shorter average length
of hospital stay if they received continuous vital signs
monitoring when compared to those receiving usual
intermittent monitoring alone. This could be attributed
to the earlier detection of complications preventing es-
calation of care to Level II/III wards and prolonging pa-
tient recovery. There was no difference in the time taken
to receive antibiotics in cases of sepsis. The cost-utility
analysis indicated that the SensiumVitals® remote moni-
toring system had the potential to be cost-saving when
compared to standard NEWS monitoring alone.
Subgroup analyses were performed in order to delin-
eate which patients would benefit most from continuous
monitoring. Patients were divided into ‘high-risk’ and
‘low-risk’ categories based on their ASA score and
whether they had a planned perioperative critical care
admission; these two factors are known to be indicators
of risk in surgical patients [16]. This subgroup analysis
showed that the difference in length of hospital stay was
particularly pronounced in ‘low-risk’ patients. This find-
ing is limited by the small subgroup numbers, but could
indicate that this group may be most likely to benefit
from continuous remote monitoring, especially if their
‘high-risk’ counterparts already receive extra clinical at-
tention due to their perceived risk of deterioration.
The findings must be interpreted within the limita-
tions of the study. Due to the feasibility nature of the
study, a formal sample size calculation was not required
and the findings were limited to descriptive statistics; no
formal statistical comparison was possible [17]. Al-
though the nature of this study does not permit conclu-
sions to be drawn about the efficacy of the intervention,
the observations give sufficient confidence that further
evaluation within a larger randomisation comparison is
justified. Such a study should consider preoperative risk
factors for complications, in addition to ASA grade, as
stratification factors to ensure that groups are balanced
in terms of frequency of complications. Consideration
should also be given to maximising protocol adherence
in the intervention group.
The potential benefits of continuous monitoring may
have been underestimated in this study due to the ex-
posure to the patch in the intervention arm. Although
most patients found the patch comfortable and felt safer
wearing it, eight participants withdrew from the
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intervention before monitoring had commenced and a
further nine participants discontinued the intervention
before discharge and within 5 days of application. Ad-
herence to the monitoring protocol could be improved
in a future trial by optimising patient comfort through
choice of device, minimising the number of false alerts
through better signal processing and encouraging par-
ticipation until discharge through regular bedside visits.
The cost-utility analysis was limited by the amount of
data concerning the influence of post-operative compli-
cations on quality of life. The results are based on the
findings of a single study which used the WHOQOL-
BREF instrument to measure quality of life following
colorectal surgery [18]. It was not possible to calculate
quality of life in terms of quality-adjusted life years
(QALYs), and therefore it was inappropriate to apply a
willingness-to-pay threshold to the cost-effectiveness
plane. As a consequence, the ICER has limited useful-
ness and there is considerable uncertainty in the model,
reflected by the large confidence interval surrounding
the ICER. Future evaluations should include quality of
life measurements using the EuroQol five dimension
scale (EQ-5D). The National Institute for Clinical Excel-
lence (NICE) Guide to the Methods of Technology Ap-
praisal expresses a preference for using the EQ-5D for
adult populations to estimate the QALY impact of differ-
ent technologies [19].
In conclusion, this study has demonstrated the
feasibility of performing a large-scale randomised
controlled trial of continuous remote monitoring
after major surgery. The purpose of this study was
not to assess the clinical efficacy of the intervention,
but the observed differences in the length of stay be-
tween the two groups suggest that this might serve
as an appropriate end-point for a larger study. This
must be balanced against the small number of par-
ticipants and the potential failure of randomisation
in the study.
The findings of this feasibility study suggest that
progression to a definitive multicentre randomised
controlled trial would be appropriate, with reassur-
ingly high rates of patient recruitment. Participants
should be individually randomised and stratified to
minimise the baseline differences between the two
treatment arms; ASA might be replaced by more spe-
cific risk stratification tools such as the PPOSSUM
(Physiological and Operative Severity Score for the
enumeration of Mortality and morbidity) score [20].
The ICC should be taken into account in the sample
size calculation to account for potential clustering of
outcomes at bay or ward level. Care should also be
taken to monitor and address inadequacies in other
areas that might mask the potential benefit of add-
itional monitoring, such as patient adherence.
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